Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to ...

Protego Biopharma is poised to start pivotal trials of its amyloid light-chain (AL) amyloidosis drug candidate, thanks to a ...

The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that could represent a step forward compared to current therapies.

Credit: Getty Images. NXC-201 is an autologous BCMA-targeted investigational chimeric antigen receptor T cell therapy. The Food and Drug Administration (FDA) has granted Orphan Drug designation to NXC ...

Neurimmune has expanded its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, an AstraZeneca company ...

In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called ...

Based on these results, Prothena has made the decision to discontinue the development of birtamimab. Topline results were announced from a phase 3 trial evaluating birtamimab in patients with amyloid ...

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation ...

Healio spoke with Joban Vaishnav, MD, director of the Johns Hopkins Comprehensive Amyloidosis Center, about the process of diagnosing amyloidosis, the importance of multidisciplinary care in patients ...

Amyloidosis is a complex disease and the program at Huntsman Cancer Institute (HCI) uses a collaborative approach to provide comprehensive medical care. Researchers are tirelessly trying to find new ...